Posts
ClinicalTrialsToday reports that PharmaNet Development Group, which is a troubled CRO, is working alongside UBS to explore alternatives, including the potential sale of the company.
The company’s share price has plunged from $39.19 in January to $1.01 in early morning trading Friday. The company has also received some letters of interest regarding the sale, but PharmaNet will not comment any further until a decision is made.
No comments:
Post a Comment